DexCom (NASDAQ:DXCM) is set to announce its earnings results after the market closes on Thursday, February 21st. Analysts expect the company to announce earnings of $0.14 per share for the quarter.

Shares of NASDAQ DXCM opened at $147.90 on Wednesday. The company has a debt-to-equity ratio of 0.60, a current ratio of 4.71 and a quick ratio of 4.43. DexCom has a 1-year low of $53.30 and a 1-year high of $155.85. The firm has a market cap of $13.19 billion, a P/E ratio of -255.00 and a beta of 0.84.

A number of research firms have commented on DXCM. Raymond James raised their target price on DexCom from $125.00 to $150.00 and gave the company an “outperform” rating in a report on Tuesday, October 23rd. Oppenheimer set a $150.00 target price on DexCom and gave the company a “buy” rating in a report on Wednesday, November 7th. Piper Jaffray Companies raised their target price on DexCom to $157.00 and gave the company an “overweight” rating in a report on Wednesday, November 7th. Stephens raised their target price on DexCom from $170.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, November 7th. Finally, Jefferies Financial Group raised their target price on DexCom to $148.00 and gave the company a “buy” rating in a report on Wednesday, November 7th. Seven research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $143.53.

In other news, CEO Kevin R. Sayer sold 6,000 shares of DexCom stock in a transaction on Monday, February 11th. The stock was sold at an average price of $148.90, for a total transaction of $893,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Andrew K. Balo sold 5,000 shares of DexCom stock in a transaction on Friday, December 14th. The stock was sold at an average price of $121.23, for a total value of $606,150.00. The disclosure for this sale can be found here. Insiders have sold a total of 50,457 shares of company stock valued at $6,687,983 in the last ninety days. Corporate insiders own 1.80% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This story was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another site, it was stolen and republished in violation of U.S. & international copyright legislation. The legal version of this story can be read at https://www.dailypolitical.com/2019/02/19/dexcom-dxcm-set-to-announce-quarterly-earnings-on-thursday.html.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Further Reading: Quiet Period Expirations Explained

Earnings History for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.